Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency

Hormone Research

Volumn 50, Issue 3, 1998, Pages 166-176

  Rikken, Berthon ^a   Van Doorn, Jaap ^b   Ringeling, André ^b   Van Den Brande, Jan Leo ^b   Massa, Guy ^a   Wit, Jan Maarten ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

GH deficiency; GH treatment; Growth evaluation; Idiopathic short stature; IGF binding proteins; Insulin like growth factors

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; BLOOD LEVEL; CHILD; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RETROSPECTIVE STUDY; SHORT STATURE; TREATMENT OUTCOME;

ADOLESCENT; BODY HEIGHT; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LIKELIHOOD FUNCTIONS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0031712476     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000023268     Document Type: Article

References (39)

1. Cowell CT: Short stature; in Brook CGD (ed): Clinical Paediatric Endocrinology, ed 3, Oxford, Blackwell Science, 1995, pp 136-172.
2. Ranke MB, Haber P: Growth hormone Stimulation tests; in Ranke MB (ed): Functional Endocrinologic Diagnostics in Children and Adolescents. Mannheim, J & J Verlag, 1992, pp 61-75.
3. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, Frasier SD, Hasegawa Y, Hintz RL, et al: Diagnostic controversy: The diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995;80:1532-1540.
4. Tillman V, Buckler JM, Kibirige MS, Price DA, Shalet SM, Wales JK, et al: Biochemical tests in the diagnosis of childhood growth hormone deficiency. J Clin Endocrinol Metab 1997;82:531-535.
5. Adan L, Souberbielle J-C, Brauner R: Diagnostic markers of permanent idiopathic growth hormone deficiency. J Clin Endocrinol Metab 1994;78:353-358.
6. Furlanetto RW, Underwood LE, Van Wyk JJ, D'Ercole AJ: Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 1977;60:648-657.
7. Reiter EO, Lovinger RD: The use of a commercially available somatomedin-C radioimmunoassay in patients with disorders of growth. J Pediatr 1981;99:720-724.
8. Moore DC, Ruvalcaba RH, Smith EK, Kelley VC: Plasma somatomedin-C as a screening test for growth hormone deficiency in children and adolescents. Horm Res 1982;16:49-55.
9. Rosenfeld RG, Wilson DM, Lee PD, Hintz RJ: Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr 1986;109: 428-433.
10. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR: A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: Its use for diagnosis of GH deficiency. J Clin Endoerinol Metab 1990;70:1292-1298.
11. Lee PD, Wilson DM, Rountree L, Hintz RL, Rosenfeld RG: Efficacy of insulin-like growth factor I levels in predicting the response to provocative growth hormone testing. Pediatr Res 1990;27:45-51.
12. Oerter KE, Sobel AM, Rose SR, Cristiano A, Malley JD, Cutler GB Jr, Baron J: Combining insulin-like growth factor-I and mean spontaneous nighttime growth hormone levels for the diagnosis of growth hormone deficiency. J Clin Endocrinol Metab 1992;75:1413-1420.
13. Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB: Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993;76:1610-1616.
14. Smith WJ, Man TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR: Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 1993;77:1294-1299.
15. Sklar C, Sarafoglou K, Whittam E: Efficacy of insulin-like growth factor binding protein 3 in predicting the growth hormone response to provocative testing in children treated with cranial irradiation. Acta Endocrinol Copenh 1993;129:511-515.
16. Hasegawa Y, Hasegawa T, Aso T, Kotoh S, Tsuchiya Y, Nose O, et al: Comparison between insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) measurement in the diagnosis of growth hormone deficiency. Endocr J 1993;40:185-190.
17. Hasegawa Y, Hasegawa T, Aso T, Kotoh S, Nose O, Ohyama Y, et al: Clinical utility of insulin-like growth factor binding protein-3 in the evaluation and treatment of short children with suspected growth hormone deficiency. Eur J Endocrinol 1994;131:27-32.
18. Hindmarsh PC, Swift PG: An assessment of growth hormone provocation tests. Arch Dis Child 1995;72:362-367.
19. Cianfarani S, Boemi S, Spagnoli S, Cappa M, Argiro G, et al: Is IGF binding protein-3 assessment helpful for the diagnosis of GH deficiency? Clin Endocrinol 1995;43:43-47.
20. Nunez SB, Municchi G, Barnes KM, Rose SR: Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 concentrations compared to stimulated and night growth hormone in the evaluation of short children - a clinical research center study. J Clin Endocrinol Metab 1996;81:1927-1932.
21. Juul A, Kastrup KW, Pedersen SA, Skakkebaek NE: Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3. J Clin Endocrinol Metab 1997; 82:1195-1201.
22. Wit JM, Kamp GA, Rikken B: Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatr Res 1996;39:295-302.
23. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, et al: Serum levels of insulin-like growth factor (IGF) binding protein 3 (IGFBP-3) in healthy infants, children, and adolescents: The relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534-2542.
24. Roede M, van Wieringen JC: Growth diagrams 1980. Netherlands Third Nationwide Survey. Tijdschr Soc Gezondheidsz 1995;63(suppl):1-34.
25. De Muinck Keizer-Schrama SMPF, Rikken B, Wynne HJ, Hokken-Koelega AC, Wit JM, Bot A: Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: Effects on auxological and biochemical parameters. J Clin Endocrinol Metab 1992;74: 898-905.
26. Rekers-Mombarg LTM, Massa GG, Wit JM: Final height of short normal children treated with growth hormone. Lancet 1996;348:681.
27. Tanner JM: Growth at Adolescence. Oxford, Blackwell, 1962.
28. Rikken B, Wit JM: Prepubertal height velocity references over a wide age range. Arch Dis Child 1992;67:1277-1280.
29. Silbergeld A, Litwin A, Bruchis S, Varsano I, Laron Z: Insulin-like growth factor I (IGF-I) in healthy children, adolescents and adults as determined by a radioimmunoassay specific for the synthetic 53-70 peptide region. Clin Endocrinol 1986;25:67-74.
30. Van den Brande JL, Hoogerbrugge CM, Beyreuther K, Roepstorff P, Jansen J, Van Buul-Offers SC: Isolation and partial characterization of IGF-like peptides from Cohn fraction IV of human plasma. Acta Endocrinol 1990; 122:683-695.
31. Jansen J, van Buul-Offers SC, Hoogerbrugge CM, van den Brande JL: Effects of a single cleavage in insulin-like growth factors I and II on binding to receptors, carrier proteins and antibodies. Biochem J 1990;266:513-520.
32. Breier BH, Gallaher BW, Gluckman PD: Radioimmunoassay for insulin-like growth factor-I: Solutions to some potential problems and pitfalls. J Endocrinol 1991;128:347-357.
33. Hokken-Koelega ACS, Hackeng WHL, Stijnen T, Wit JM, de Muinck Keizer-Schrama SMPF, Drop SLS: Twenty-four hour plasma growth hormone (GH) profiles, urinary GH excretion and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation. J Clin Endocrinol Metab 1990;71:688-695.
34. De Vries BBA, Robinson H, Stolte I, Tjon Pian Gi CV, Dijkstra PF, van Doom J, et al: General overgrowth in the fragile X syndrome: Variability in the phenotypic expression of the FMR1 gene mutation. J Med Genet 1995;32: 764-766.
35. Cole TJ: The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990;44:45-60.
36. Sackett DL, Haynes RB, Guyatt GH, Tugwell P (eds): The Interpretation of Diagnostic Data; in Clinical Epidemiology, ed 2. Boston, Little, Brown, 1991, pp 69-152.
37. Rekers-Mombarg LTM, Massa GG, Wit JM, Matranga AMC, Cox L, Buckler JMH, et al: Growth hormone therapy with three dosage regimens in children with idiopathic short stature. J Pediatr 1998;132:445-460.
38. Giordano G: Somatotropin and somatomedin in the diagnosis of growth hormone dependent hyposomia. Minerva Med 1979;70:1967-1984.
39. Rikken B, Massa GG, Wit JM, and Dutch Growth Hormone Working Group: Final height in a large cohort of Dutch patients with growth hormone deficiency treated with growth hormone. Horm Res 1995;43:135-137.